Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05887713 · ClinicalTrials.gov registry record · NA
Novel Mental Health Therapies to Improve Military Readiness
A NA study of Anxiety and Cognitive Behavioral Therapy, sponsored by David Moss.
- Recruiting
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT05887713: Recruiting NA study of Anxiety and Cognitive Behavioral Therapy, sponsored by David Moss.
NCT05887713 is a NA study of Anxiety and Cognitive Behavioral Therapy that is actively recruiting participants, run by David Moss. The registered enrollment target is 160 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05887713, a NA study of Anxiety and Cognitive Behavioral Therapy, is actively recruiting participants, sponsored by David Moss.
- RECRUITING
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the efficacy of CES as a therapy to treat and mitigate symptoms of generalized anxiety in DoD beneficiaries in a prospective clinical trial and compare this to sham (placebo) CES.
Primary Outcome
BAI total scores range from 0 to 63; higher total scores indicate more severe anxiety symptoms. Scores are clinically categorized as 0-7 (minimal anxiety) 8-15 (mild anxiety), 16-25 (moderate anxiety), and 26-63 (severe anxiety). The BAI and HAM-A are mildly correlated. BAI will be treated as normally distributed allowing parametric statistical methods to be used. Baseline BAI will be obtained.
Conditions Studied
Interventions
- DEVICE Sham Comparator
- DEVICE Experimental: Alpha-Stim 100
Study Locations (1)
Nevada
- Mike O'Callaghan Military Medical Center - Nellis Air Force Base
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2025-12 |
| Phase | NA |
What NCT05887713 shows while recruiting
NCT05887713 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (64% lower).
The record links to 5 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Sham Comparator is the first listed.
NCT05887713 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT05887713 about?
NCT05887713 is a clinical study titled "Novel Mental Health Therapies to Improve Military Readiness". To evaluate the efficacy of CES as a therapy to treat and mitigate symptoms of generalized anxiety in DoD beneficiaries in a prospective clinical trial and compare this to sham (placebo) CES.
What is the current status of trial NCT05887713?
This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2024-01-01. Estimated completion is 2025-12.
What conditions does trial NCT05887713 study?
This clinical trial studies the following conditions: Anxiety, Cognitive Behavioral Therapy, Heart Rate Variability, Alpha Stim, Cranial Electrotherapy Stimulation.
What interventions are being tested in trial NCT05887713?
The interventions under investigation include: Sham Comparator (DEVICE), Experimental: Alpha-Stim 100 (DEVICE).
Who is sponsoring clinical trial NCT05887713?
This trial is sponsored by David Moss, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05887713 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05887713's enrollment target sits among peer trials
160 105th of 364 higher than 257 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
-
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
RECRUITING · NA
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI